Pretzel Therapeutics Inc. has patented heterocycle-containing compounds acting as Lon protease homolog, mitochondrial (LONP1) inhibitors. They are reported to be useful for the treatment of cancer, aging, neurodegeneration and metabolic diseases.
Prothena Biosciences Ltd. has developed dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitors reported to be useful for the treatment of Alzheimer’s disease.
Research at Betta Pharmaceuticals Co. Ltd. has led to the identification of new GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Shionogi & Co. Ltd. has reported aromatic heterocyclic compounds acting as glucagon-like peptide 1 receptor (GLP-1R) agonists and reported to be useful for the treatment of obesity and type 2 diabetes.
Menin (MEN1)/MLL interaction inhibitors are reported in a Bala Therapeutics Inc. patent as potentially useful for the treatment of cancer and diabetes.
A Cytosite Biopharma Inc. patent describes prodrugs of granzyme B-targeting compounds reported to be useful as granzyme B-imaging agents for the diagnosis of cancer.
Vertex Pharmaceuticals Inc. has developed spirocyclic inhibitors of apolipoprotein L1 (APOL1) reported to be useful for the treatment of pancreatic cancer and focal segmental glomerulosclerosis.
Research at Humanwell Healthcare (Group) Co. Ltd. has led to the identification of interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.
Incyte Corp. has patented bicyclic amines acting as cyclin-dependent kinase 12 (CDK12) inhibitors and reported to be useful for the treatment of cancer.
RSS